Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):579-584. doi: 10.1182/hematology.2020000144.
Cellular-redirecting therapies, including bispecific T-cell engagers and chimeric antigen receptor (CAR) T cells, are rapidly changing the treatment landscape of hematologic malignancies and solid tumor malignancies. I will discuss the unique safety profile and logistical aspects that pose challenges and opportunities for the safe and successful delivery of these therapies. Close interaction, communication, and established partnerships between the primary oncologist, the disease specialist, and the immune effector cell provider will be needed to provide optimal care longitudinally for any patient. I will discuss practical ways for any program to deliver these therapies and how future advances may widen availability beyond just a few centers.
细胞重定向疗法，包括双特异性 T 细胞衔接子和嵌合抗原受体 (CAR) T 细胞，正在迅速改变血液系统恶性肿瘤和实体瘤恶性肿瘤的治疗格局。我将讨论这些疗法在安全有效应用方面面临的挑战和机遇所具有的独特安全性和后勤方面问题。为了使任何患者都能获得最佳的长期护理，初级肿瘤学家、疾病专家和免疫效应细胞提供者之间需要进行密切的互动、沟通和建立伙伴关系。我将讨论任何项目提供这些疗法的实际方法，以及未来的进展如何使这些疗法的应用不仅仅局限于少数几个中心。
